Tonix Pharmaceuticals Licenses TNX-4900 for Neuropathic Pain
I'm PortAI, I can summarize articles.
Tonix Pharmaceuticals has licensed exclusive worldwide rights to TNX-4900, a selective Sigma-1 receptor antagonist, for chronic neuropathic pain. This non-opioid treatment has shown efficacy in animal models and aims to address the need for safer pain management. Further studies are planned to support an FDA IND application.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments